Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP · NASDAQ Capital Market
+$0.70 today
Vol 0.37M · Avg 0.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-50.6%
avg -108.5%
ROIC
-51.0%
avg -104.3%
ROA
-44.7%
avg -88.1%
Analysis
ROA is currently the strongest return metric at -44.7% versus its period average of -88.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Seth Lederman | Co-Founder, President, Chief Executive Officer & Chairman | $1.30M | — | 68 | $9,005.00 | 0.06% |
Mrs. Jessica Edgar Morris | Chief Operating Officer | $784,362.00 | — | — | $39,012.00 | 0.24% |
Gregory Sullivan | Chief Medical Officer & Secretary | $778,768.00 | — | 60 | $39,012.00 | 0.24% |
Bradley Saenger | Chief Financial Officer & Treasurer | $754,394.00 | — | 52 | $39,012.00 | 0.24% |
Darryl Rideout | Executive Vice President of Experimental Chemistry | — | — | — | — | — |
Sina Bavari | Executive Vice President of Infectious Disease Research & Development | — | — | — | — | — |
Zeil Rosenberg | Executive Vice President of Medical | — | — | — | — | — |
Thomas Englese | Executive Vice President of Commercial Operations | — | — | 52 | — | — |
Irina Ishak | General Counsel | — | — | — | — | — |
Siobhan Fogarty | Chief Technical Officer | — | — | 57 | $39,012.00 | 0.24% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$427,710.54
Sells
0
$0.00
Net Sentiment
+$427,710.54
Net buying
Most Active
LEDERMAN SETH
3 transactions
Analysis
Insiders reported 6 buys worth $427,710.54 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $427,710.54. LEDERMAN SETH was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
$214.02M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages TNXP?
Tonix Pharmaceuticals Holding Corp. (TNXP) lists 10 active executives. The top listed executive is Gregory Sullivan, Chief Medical Officer & Secretary.
Are TNXP insiders buying or selling?
Recent insider activity shows net buying of $63.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.